用于增加轻度认知衰退的老年人参与度的干预措施:系统性审查
Emma Ward1, Kylie Wales2, Laura Jolliffe3
1Emma Ward, BOccTherapy, is Occupational Therapist, Occupational Therapy Department, Alfred Hospital, Melbourne, Victoria, Australia, and Adjunct Research Associate, Department of Neuroscience, Monash University, Melbourne, Victoria, Australia; e.ward@alfred.org.au.
概括
职业治疗干预措施有效地提高了老年轻度认知衰退的参与有意义的活动. 这些益处在治疗后持续长达六个月,尽管需要更多的研究.
科学领域:
- 老年学是一门学科.
- 认知康复 认知康复 认知康复
- 职业疗法 职业疗法 职业疗法
背景情况:
- 轻度认知衰退 (MCD) 影响老年人,并可能发展为痴呆症.
- 职业治疗师 (OT) 对于维持参与这些人群有意义的活动至关重要.
研究的目的:
- 审查MCD老年人的职业治疗 (OT) 干预措施.
- 评估这些干预措施对参与结果的有效性.
主要方法:
- 从CINAHL,MEDLINE和Embase到2024年8月的随机对照试验 (RCT) 的系统审查和元分析.
- 包括的研究评估了老年人MCD的OT干预措施.
- 科克莱恩偏差风险工具 (ROB2) 评估了研究质量;结果通过叙述和元分析进行了综合.
主要成果:
- 十项研究 (11篇文章) 符合纳入标准,重点是认知训练 (补救或补偿).
- 八项研究的元分析表明,OT干预措施显著提高了治疗后立即 (SMD = 0.504) 和6个月 (SMD = 0.271) 的参与率.
- 结果中注意到了相当大的异质性.
结论:
- 提供OT的干预措施有效地提高了MCD的老年人参与度.
- 治疗后立即和长达六个月后都会观察到益处.
- 需要进一步的研究来加强对这些发现的信心.
相关概念视频
Cognitive Development During Adulthood
780
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
780
Pharmacodynamics in Geriatric Patients: Effects of Age
188
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
188
Alzheimer's Disease: Treatment
824
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
824
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
560
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
560
Drug Dosing: Geriatric Patients
227
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
227
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


